This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Braden, G. A. Articles by FitzGerald, G. A. Search for Related Content PubMed PubMed Citation Articles by Braden, G. A. Articles by FitzGerald, G. A.

Circulation, Vol 84, 679-685, Copyright © 1991 by American Heart Association

ARTICLES

Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin

GA Braden, HR Knapp and GA FitzGerald
Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN 37232.

BACKGROUND. Percutaneous transluminal coronary angioplasty (PTCA) is an acute, localized stimulus to platelet and vascular function. Periprocedural cardiovascular complications are reduced by moderate- dose aspirin (ASA), presumably due to inhibition of thromboxane (TX) A2. METHODS AND RESULTS. Excretion of TXA2 and prostacyclin (PGI2) metabolites in urine increased during PTCA. Pretreatment for 3 days with either moderate- (325 mg/day) or low-dose (80 mg/day) ASA inhibited the increase in both eicosanoids. Pretreatment for 3 weeks with fish oil (10 g/day) only partially suppressed TXA2. Formation of trienoic eicosanoids and accumulation of omega-3 fatty acids in platelet membranes confirmed fish oil ingestion. Although basal PGI2 was not inhibited, the PTCA-related increment was suppressed. CONCLUSIONS. PTCA results in an acute, transient alteration of eicosanoid biosynthesis consistent with accelerated platelet-vascular interactions. Pretreatment for 3 days with moderate or low doses of ASA suppresses TXA to a similar extent during PTCA, and their effects on acute cardiovascular complications of this procedure are likely to be comparable. It is unlikely that even prolonged pretreatment with fish oil can substitute for the platelet inhibitory action of ASA during PTCA. Suppression of PGI2 may contribute to the residual acute periprocedural complication rate in patients taking ASA.

This article has been cited by other articles:

				M. Dona, G. Fredman, J. M. Schwab, N. Chiang, M. Arita, A. Goodarzi, G. Cheng, U. H. von Andrian, and C. N. Serhan Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets Blood, August 1, 2008; 112(3): 848 - 855. [Abstract] [Full Text] [PDF]

				J. A. Lawson, S. Kim, W. S. Powell, G. A. FitzGerald, and J. Rokach Oxidized derivatives of {omega}-3 fatty acids: identification of IPF3{alpha}-VI in human urine J. Lipid Res., November 1, 2006; 47(11): 2515 - 2524. [Abstract] [Full Text] [PDF]

				D. Kearney, A. Byrne, P. Crean, D. Cox, and D. J. Fitzgerald Optimal suppression of thromboxane a2 formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor J. Am. Coll. Cardiol., February 18, 2004; 43(4): 526 - 531. [Abstract] [Full Text] [PDF]

				Y. Cheng, S. C. Austin, B. Rocca, B. H. Koller, T. M. Coffman, T. Grosser, J. A. Lawson, and G. A. FitzGerald Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 Science, April 19, 2002; 296(5567): 539 - 541. [Abstract] [Full Text] [PDF]

				E. Connolly, D. J. Bouchier-Hayes, E. Kaye, A. Leahy, D. Fitzgerald, and O. Belton Cyclooxygenase Isozyme Expression and Intimal Hyperplasia in a Rat Model of Balloon Angioplasty J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 393 - 398. [Abstract] [Full Text] [PDF]

				F. Catella-Lawson Vascular biology of thrombosis: Platelet-vessel wall interactions and aspirin effects Neurology, September 1, 2001; 57(90002): S5 - 7. [Abstract] [Full Text]

				G. A. FitzGerald and C. Patrono The Coxibs, Selective Inhibitors of Cyclooxygenase-2 N. Engl. J. Med., August 9, 2001; 345(6): 433 - 442. [Full Text] [PDF]

				D. Pratico, Y. Cheng, and G. A. FitzGerald TP or Not TP: Primary Mediators in a Close Runoff? Arterioscler Thromb Vasc Biol, July 1, 2000; 20(7): 1695 - 1698. [Full Text] [PDF]

				C. P. Burns, S. Halabi, G. H. Clamon, V. Hars, B. A. Wagner, R. J. Hohl, E. Lester, J. J. Kirshner, V. Vinciguerra, and E. Paskett Phase I Clinical Study of Fish Oil Fatty Acid Capsules for Patients with Cancer Cachexia: Cancer and Leukemia Group B Study 9473 Clin. Cancer Res., December 1, 1999; 5(12): 3942 - 3947. [Abstract] [Full Text] [PDF]

				B. F. McAdam, F. Catella-Lawson, I. A. Mardini, S. Kapoor, J. A. Lawson, and G. A. FitzGerald Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2 PNAS, January 5, 1999; 96(1): 272 - 277. [Abstract] [Full Text] [PDF]

				A. Byrne, N. Moran, M. Maher, N. Walsh, P. Crean, and D. J. Fitzgerald Continued Thromboxane A2 Formation Despite Administration of a Platelet Glycoprotein IIb/IIIa Antagonist in Patients Undergoing Coronary Angioplasty Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 3224 - 3229. [Abstract] [Full Text]